- Home
- DRMA vs AEMD Comparison
DRMA vs AEMD Comparison
Compare DRMA & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- AEMD
- Stock Information
- Founded
- DRMA 2014
- AEMD 1984
- Country
- DRMA United States
- AEMD United States
- Employees
- DRMA N/A
- AEMD N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- AEMD Medical/Dental Instruments
- Sector
- DRMA Health Care
- AEMD Health Care
- Exchange
- DRMA Nasdaq
- AEMD Nasdaq
- Market Cap
- DRMA 3.6M
- AEMD 4.1M
- IPO Year
- DRMA 2021
- AEMD N/A
- Fundamental
- Price
- DRMA $5.99
- AEMD $0.76
- Analyst Decision
- DRMA Strong Buy
- AEMD Buy
- Analyst Count
- DRMA 1
- AEMD 2
- Target Price
- DRMA $10.00
- AEMD $28.75
- AVG Volume (30 Days)
- DRMA 32.3K
- AEMD 8.9M
- Earning Date
- DRMA 11-12-2025
- AEMD 11-12-2025
- Dividend Yield
- DRMA N/A
- AEMD N/A
- EPS Growth
- DRMA N/A
- AEMD N/A
- EPS
- DRMA N/A
- AEMD N/A
- Revenue
- DRMA N/A
- AEMD N/A
- Revenue This Year
- DRMA N/A
- AEMD N/A
- Revenue Next Year
- DRMA N/A
- AEMD N/A
- P/E Ratio
- DRMA N/A
- AEMD N/A
- Revenue Growth
- DRMA N/A
- AEMD N/A
- 52 Week Low
- DRMA $5.04
- AEMD $0.60
- 52 Week High
- DRMA $24.90
- AEMD $8.44
- Technical
- Relative Strength Index (RSI)
- DRMA 54.71
- AEMD 40.15
- Support Level
- DRMA $5.27
- AEMD $0.70
- Resistance Level
- DRMA $5.74
- AEMD $0.82
- Average True Range (ATR)
- DRMA 0.40
- AEMD 0.16
- MACD
- DRMA 0.07
- AEMD -0.06
- Stochastic Oscillator
- DRMA 80.17
- AEMD 10.34
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.